Oxidative damage in Parkinson's disease.

NADPH oxidase 1-mediated oxidative stress leads to dopamine neuron death in Parkinson's disease. Antioxid Redox Signal (2012) 1.12

LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinson's disease patients: reversal by gene correction. Neurobiol Dis (2013) 1.10

Mitochondrial DNA damage: molecular marker of vulnerable nigral neurons in Parkinson's disease. Neurobiol Dis (2014) 1.00

Neuroprotective efficacy of a new brain-penetrating C-Abl inhibitor in a murine Parkinson's disease model. PLoS One (2013) 0.97

Enhanced autophagy from chronic toxicity of iron and mutant A53T α-synuclein: implications for neuronal cell death in Parkinson disease. J Biol Chem (2011) 0.96

Glutaredoxin 1 protects dopaminergic cells by increased protein glutathionylation in experimental Parkinson's disease. Antioxid Redox Signal (2012) 0.85

LC/MS analysis of cardiolipins in substantia nigra and plasma of rotenone-treated rats: Implication for mitochondrial dysfunction in Parkinson's disease. Free Radic Res (2015) 0.82

Neuronal failure in Alzheimer's disease: a view through the oxidative stress looking-glass. Neurosci Bull (2014) 0.81

Biphasic regulation of lysosomal exocytosis by oxidative stress. Cell Calcium (2016) 0.75

Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat Neurosci (2002) 4.15

Mechanism of toxicity in rotenone models of Parkinson's disease. J Neurosci (2003) 3.30

Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp Neurol (2003) 2.85

An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J Neurosci (2002) 2.54

N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking. J Neurosci (2008) 2.18

Animal models of Parkinson's disease. Bioessays (2002) 2.05

A highly reproducible rotenone model of Parkinson's disease. Neurobiol Dis (2009) 1.92

Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system. Neurobiol Dis (2006) 1.83

Rotenone model of Parkinson disease: multiple brain mitochondria dysfunctions after short term systemic rotenone intoxication. J Biol Chem (2005) 1.65

Environment, mitochondria, and Parkinson's disease. Neuroscientist (2002) 1.63

Gene expression profiling of rat midbrain dopamine neurons: implications for selective vulnerability in parkinsonism. Neurobiol Dis (2005) 1.57

Pseudotype-dependent lentiviral transduction of astrocytes or neurons in the rat substantia nigra. Exp Neurol (2010) 1.56

Role of external pallidal segment in primate parkinsonism: comparison of the effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism and lesions of the external pallidal segment. J Neurosci (2004) 1.48

Ubiquitin-proteasome system and Parkinson's diseases. Exp Neurol (2005) 1.47

Selective microglial activation in the rat rotenone model of Parkinson's disease. Neurosci Lett (2003) 1.46

Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures. Brain Res Mol Brain Res (2005) 1.45

Mechanism of toxicity of pesticides acting at complex I: relevance to environmental etiologies of Parkinson's disease. J Neurochem (2007) 1.44

Neurotoxic in vivo models of Parkinson's disease recent advances. Prog Brain Res (2010) 1.41

Mechanistic approaches to Parkinson's disease pathogenesis. Brain Pathol (2002) 1.39

Paraquat neurotoxicity is distinct from that of MPTP and rotenone. Toxicol Sci (2005) 1.38

Protection by the NDI1 gene against neurodegeneration in a rotenone rat model of Parkinson's disease. PLoS One (2008) 1.32

The role of environmental exposures in neurodegeneration and neurodegenerative diseases. Toxicol Sci (2011) 1.31

Chronic rotenone exposure reproduces Parkinson's disease gastrointestinal neuropathology. Neurobiol Dis (2009) 1.24

Obligatory role for complex I inhibition in the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Toxicol Sci (2006) 1.17

Peroxiredoxin-2 protects against 6-hydroxydopamine-induced dopaminergic neurodegeneration via attenuation of the apoptosis signal-regulating kinase (ASK1) signaling cascade. J Neurosci (2011) 1.13

A novel transferrin/TfR2-mediated mitochondrial iron transport system is disrupted in Parkinson's disease. Neurobiol Dis (2009) 1.11

We need something better, and we need it now: fetal striatal transplantation in Huntington's disease? Neurology (2002) 1.10

In vitro effects of polyglutamine tracts on Ca2+-dependent depolarization of rat and human mitochondria: relevance to Huntington's disease. Arch Biochem Biophys (2003) 1.05

Lessons from the rotenone model of Parkinson's disease. Trends Pharmacol Sci (2010) 1.05

Oxidative damage to macromolecules in human Parkinson disease and the rotenone model. Free Radic Biol Med (2013) 1.03

Rotenone, deguelin, their metabolites, and the rat model of Parkinson's disease. Chem Res Toxicol (2004) 1.01

Mitochondrial iron metabolism and its role in neurodegeneration. J Alzheimers Dis (2010) 1.01

Blockade of cannabinoid type 1 receptors augments the antiparkinsonian action of levodopa without affecting dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys. J Pharmacol Exp Ther (2007) 0.99

Ca2+-induced permeability transition in human lymphoblastoid cell mitochondria from normal and Huntington's disease individuals. Mol Cell Biochem (2005) 0.99

Protection against oxidant-induced apoptosis by mitochondrial thioredoxin in SH-SY5Y neuroblastoma cells. Toxicol Appl Pharmacol (2006) 0.98

Toxin models of mitochondrial dysfunction in Parkinson's disease. Antioxid Redox Signal (2011) 0.97

Automated imaging system for fast quantitation of neurons, cell morphology and neurite morphometry in vivo and in vitro. Neurobiol Dis (2012) 0.95

Melatonin treatment potentiates neurodegeneration in a rat rotenone Parkinson's disease model. J Neurosci Res (2010) 0.94

Gene-environment interactions in Parkinson's disease: specific evidence in humans and mammalian models. Neurobiol Dis (2012) 0.94

Hypokinesia and reduced dopamine levels in zebrafish lacking β- and γ1-synucleins. J Biol Chem (2011) 0.94

A FRET-based method to study protein thiol oxidation in histological preparations. Free Radic Biol Med (2008) 0.91

NeuN is not a reliable marker of dopamine neurons in rat substantia nigra. Neurosci Lett (2009) 0.90

Neurodegenerative disease: pink, parkin and the brain. Nature (2006) 0.89

Quantitative evaluation of the effects of mitochondrial permeability transition pore modifiers on accumulation of calcium phosphate: comparison of rat liver and brain mitochondria. Arch Biochem Biophys (2004) 0.89

PCR based determination of mitochondrial DNA copy number in multiple species. Methods Mol Biol (2015) 0.88

Pilocapine alters NMDA receptor expression and function in hippocampal neurons: NADPH oxidase and ERK1/2 mechanisms. Neurobiol Dis (2011) 0.88

Overexpression of VMAT-2 and DT-diaphorase protects substantia nigra-derived cells against aminochrome neurotoxicity. Biochim Biophys Acta (2012) 0.87

Differential expression and ser897 phosphorylation of striatal N-methyl-d-aspartate receptor subunit NR1 in animal models of Parkinson's disease. Exp Neurol (2004) 0.87

Pupillary unrest correlates with arousal symptoms and motor signs in Parkinson disease. Mov Disord (2011) 0.87

Regulation of dopamine receptor and neuropeptide expression in the basal ganglia of monkeys treated with MPTP. Exp Neurol (2004) 0.87

DJ-1 expression modulates astrocyte-mediated protection against neuronal oxidative stress. J Mol Neurosci (2012) 0.86

Prolongation of levodopa responses by glycineB antagonists in parkinsonian primates. Ann Neurol (2004) 0.85

Autonomic insufficiency in pupillary and cardiovascular systems in Parkinson's disease. Parkinsonism Relat Disord (2010) 0.83

Expression of human E46K-mutated α-synuclein in BAC-transgenic rats replicates early-stage Parkinson's disease features and enhances vulnerability to mitochondrial impairment. Exp Neurol (2012) 0.82

shRNA targeting α-synuclein prevents neurodegeneration in a Parkinson's disease model. J Clin Invest (2015) 0.82

A rapid and sensitive automated image-based approach for in vitro and in vivo characterization of cell morphology and quantification of cell number and neurite architecture. Curr Protoc Cytom (2014) 0.81

Neuron-selective changes in RNA transcripts related to energy metabolism in toxic models of parkinsonism in rodents. Neurobiol Dis (2010) 0.81

Acute mitochondrial and chronic toxicological effects of 1-methyl-4-phenylpyridinium in human neuroblastoma cells. Neurotoxicology (2002) 0.81

Mouse ES cells overexpressing DNMT1 produce abnormal neurons with upregulated NMDA/NR1 subunit. Differentiation (2011) 0.80

Is Axonal Degeneration a Key Early Event in Parkinson's Disease? J Parkinsons Dis (2016) 0.76

Parkinson's disease: animal models. Handb Clin Neurol (2007) 0.75

Regulation of complex I by Engrailed is complex too. Nat Neurosci (2011) 0.75

Update on Huntington's disease. Curr Neurol Neurosci Rep (2006) 0.75